Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Tejas Patil

Concepts (162)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Carcinoma, Non-Small-Cell Lung
40
2026
1195
6.590
Why?
Lung Neoplasms
45
2026
2675
5.020
Why?
Protein Kinase Inhibitors
16
2026
983
1.800
Why?
Antineoplastic Combined Chemotherapy Protocols
10
2026
1998
1.780
Why?
Acrylamides
7
2025
74
1.700
Why?
Aniline Compounds
7
2025
120
1.660
Why?
Mutation
19
2026
4093
1.580
Why?
ErbB Receptors
15
2025
636
1.290
Why?
Antibodies, Monoclonal
3
2025
1512
1.200
Why?
B7-H1 Antigen
3
2026
245
1.100
Why?
Protein-Tyrosine Kinases
7
2023
429
0.920
Why?
Receptor, ErbB-3
1
2025
48
0.910
Why?
Proto-Oncogene Proteins
7
2023
616
0.900
Why?
Pleural Neoplasms
3
2026
31
0.900
Why?
Neuregulin-1
1
2025
50
0.900
Why?
Drug Resistance, Neoplasm
6
2026
893
0.870
Why?
Pemetrexed
1
2024
40
0.850
Why?
Pyrimidines
11
2026
532
0.840
Why?
Immunoconjugates
1
2025
138
0.790
Why?
Brain Neoplasms
6
2024
1325
0.730
Why?
Proto-Oncogene Proteins c-ret
4
2026
41
0.660
Why?
Mesothelioma
3
2026
50
0.610
Why?
Antibodies, Monoclonal, Humanized
2
2025
992
0.610
Why?
Gene Rearrangement
6
2026
156
0.600
Why?
Medical Oncology
4
2026
345
0.580
Why?
Aged, 80 and over
12
2026
8391
0.570
Why?
Adenocarcinoma
3
2026
927
0.550
Why?
Neoplasms
4
2026
2954
0.520
Why?
Aged
24
2026
26432
0.510
Why?
Middle Aged
29
2026
36619
0.500
Why?
Indoles
7
2025
511
0.490
Why?
Pleural Effusion, Malignant
1
2016
12
0.470
Why?
Peritoneal Neoplasms
1
2016
103
0.440
Why?
Biomarkers, Tumor
6
2026
1339
0.430
Why?
Small Cell Lung Carcinoma
2
2026
125
0.420
Why?
Pyrazoles
6
2026
517
0.400
Why?
Humans
55
2026
146342
0.400
Why?
Survival Rate
7
2026
2092
0.400
Why?
Carcinoma, Squamous Cell
4
2026
628
0.400
Why?
Retrospective Studies
21
2026
17438
0.380
Why?
Adult
18
2026
41087
0.360
Why?
Neoplasm Staging
7
2026
1488
0.360
Why?
Disease Progression
4
2025
2867
0.350
Why?
Female
31
2026
79499
0.340
Why?
Male
28
2026
73396
0.330
Why?
Molecular Targeted Therapy
5
2026
447
0.300
Why?
Antineoplastic Agents
5
2024
2219
0.300
Why?
Proto-Oncogene Proteins p21(ras)
5
2023
250
0.290
Why?
Prognosis
5
2026
4351
0.280
Why?
Lung
2
2018
4122
0.280
Why?
Proto-Oncogene Proteins c-met
3
2026
76
0.270
Why?
Pyridines
4
2026
610
0.240
Why?
Carcinoma, Adenosquamous
1
2026
9
0.240
Why?
Neoplasm Metastasis
3
2024
693
0.230
Why?
Genomics
3
2026
853
0.220
Why?
Programmed Cell Death 1 Receptor
2
2025
268
0.220
Why?
Thymus Neoplasms
1
2025
30
0.220
Why?
Thymoma
1
2025
38
0.220
Why?
Central Nervous System
3
2023
278
0.220
Why?
Thoracic Neoplasms
1
2025
40
0.220
Why?
Lactams
2
2025
28
0.210
Why?
Neoadjuvant Therapy
2
2024
475
0.200
Why?
Oncogenes
3
2022
113
0.200
Why?
Aminopyridines
2
2025
128
0.190
Why?
Oncogene Addiction
1
2023
6
0.190
Why?
Research Personnel
1
2025
190
0.190
Why?
Radiosurgery
2
2024
398
0.180
Why?
Chemoradiotherapy
1
2024
238
0.180
Why?
Soft Tissue Neoplasms
1
2023
133
0.180
Why?
Clinical Trials as Topic
2
2025
1064
0.170
Why?
Acetonitriles
1
2021
12
0.170
Why?
Sarcoma
1
2023
209
0.160
Why?
Bone Neoplasms
1
2023
272
0.160
Why?
Circulating Tumor DNA
1
2020
50
0.150
Why?
Gene Amplification
1
2019
116
0.150
Why?
Lactams, Macrocyclic
1
2019
51
0.150
Why?
Tracheal Neoplasms
1
2019
11
0.150
Why?
Genes, erbB-1
1
2018
21
0.140
Why?
Piperazines
1
2021
368
0.140
Why?
Oncogene Proteins
1
2018
61
0.140
Why?
Thromboembolism
1
2018
129
0.130
Why?
Positron Emission Tomography Computed Tomography
1
2018
122
0.130
Why?
Disease-Free Survival
2
2017
778
0.130
Why?
Transcriptome
1
2024
1068
0.130
Why?
Computed Tomography Angiography
1
2018
151
0.130
Why?
Biomarkers, Pharmacological
1
2017
26
0.130
Why?
Smad4 Protein
1
2017
33
0.130
Why?
Gene Deletion
1
2018
385
0.130
Why?
Erlotinib Hydrochloride
1
2017
71
0.120
Why?
Health Services Needs and Demand
1
2019
287
0.120
Why?
Antineoplastic Agents, Immunological
1
2018
200
0.120
Why?
Follow-Up Studies
3
2020
5439
0.110
Why?
Carbazoles
2
2026
53
0.110
Why?
Neoplasm Recurrence, Local
2
2023
1160
0.110
Why?
Piperidines
2
2026
225
0.100
Why?
Prospective Studies
1
2025
8123
0.090
Why?
Treatment Outcome
5
2026
11821
0.090
Why?
Colorectal Neoplasms
1
2021
874
0.090
Why?
Liver Neoplasms
1
2018
776
0.090
Why?
Tomography, X-Ray Computed
2
2022
2786
0.090
Why?
Mice
2
2026
18297
0.090
Why?
Smoking
1
2018
1486
0.080
Why?
Gene Fusion
2
2023
31
0.080
Why?
Incidence
1
2018
2936
0.080
Why?
Quality of Life
1
2022
3200
0.070
Why?
Immunotherapy
2
2026
671
0.070
Why?
Survival Analysis
2
2025
1378
0.070
Why?
Animals
2
2026
38106
0.060
Why?
Biomarkers
1
2017
4340
0.060
Why?
Myasthenia Gravis
1
2025
24
0.050
Why?
Pleura
1
2024
28
0.050
Why?
Consolidation Chemotherapy
1
2024
11
0.050
Why?
Tropomyosin
1
2023
10
0.050
Why?
Receptor, trkA
1
2023
17
0.050
Why?
Canada
1
2025
432
0.050
Why?
Peritoneum
1
2023
44
0.050
Why?
Kelch-Like ECH-Associated Protein 1
1
2023
15
0.050
Why?
Sequence Deletion
1
2023
190
0.050
Why?
Platinum
1
2023
48
0.050
Why?
Taxoids
1
2023
115
0.050
Why?
Response Evaluation Criteria in Solid Tumors
1
2022
21
0.050
Why?
High-Throughput Nucleotide Sequencing
1
2026
539
0.050
Why?
NF-E2-Related Factor 2
1
2023
96
0.040
Why?
Exons
1
2023
361
0.040
Why?
Thyroid Neoplasms
1
2026
380
0.040
Why?
Oncogene Proteins, Fusion
1
2023
213
0.040
Why?
Young Adult
1
2018
14330
0.040
Why?
Appendiceal Neoplasms
1
2021
28
0.040
Why?
Meningeal Neoplasms
1
2021
95
0.040
Why?
Receptor Protein-Tyrosine Kinases
1
2022
227
0.040
Why?
Precision Medicine
1
2024
462
0.040
Why?
Signal Transduction
2
2026
5246
0.030
Why?
Protein Conformation
1
2021
916
0.030
Why?
Cell Line, Tumor
1
2026
3545
0.030
Why?
Algorithms
1
2025
1849
0.030
Why?
Topoisomerase I Inhibitors
1
2017
20
0.030
Why?
Gene Expression Profiling
1
2024
1792
0.030
Why?
Etoposide
1
2017
169
0.030
Why?
Proto-Oncogene Proteins B-raf
1
2018
231
0.030
Why?
Cranial Irradiation
1
2017
85
0.030
Why?
Electronic Health Records
1
2024
1210
0.030
Why?
Kaplan-Meier Estimate
1
2018
970
0.030
Why?
Deoxycytidine
1
2017
219
0.030
Why?
Salvage Therapy
1
2017
166
0.030
Why?
Registries
1
2024
2400
0.030
Why?
Multivariate Analysis
1
2018
1543
0.030
Why?
Down-Regulation
1
2017
614
0.030
Why?
DNA Repair
1
2017
255
0.030
Why?
United States
2
2025
16136
0.030
Why?
Transforming Growth Factor beta
1
2017
467
0.030
Why?
Cohort Studies
1
2024
6077
0.030
Why?
Combined Modality Therapy
1
2017
1271
0.020
Why?
Databases, Factual
1
2019
1493
0.020
Why?
Mass Screening
1
2020
1307
0.020
Why?
Gene Expression Regulation, Neoplastic
1
2017
1432
0.020
Why?
Reproducibility of Results
1
2018
3416
0.020
Why?
Magnetic Resonance Imaging
1
2023
3926
0.020
Why?
Genetic Predisposition to Disease
1
2018
2488
0.020
Why?
Pregnancy
1
2022
7230
0.020
Why?
Time Factors
1
2020
7109
0.020
Why?
Adolescent
1
2023
22557
0.010
Why?
Child
1
2023
22693
0.010
Why?
Patil's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)